Private Equity
The sovereign fund, which has received US antitrust approval to raise its stake in Merrill Lynch, has doubled its profits to S$18.2 billion. Though it predicts continued credit market fallout will dampen the economy, Temasek has indicated it will continue to do direct deals in financial services.
3 min read · 04 January 2013
The India-focused fund manager is backing the expansion of a Mumbai-based pre-school operator with a $7m capital infusion.
2 min read · 04 January 2013
The Asia-focused private equity firm is backing the expansion plans of RSP Design Consultants - Baring's second investment in the construction and infrastructure services sector in India this year.
2 min read · 04 January 2013
Olympus has made its fourth Chinese investment with a growth capital infusion in Zhongwang International, the world's third largest aluminium profile company.
1 min read · 04 January 2013
A Series C funding round for Spring Wireless represents NEA's first foray into Latin America. Goldman Sachs was also among the backers of the telecom company, which anticipates an IPO in 2009.
2 min read · 04 January 2013
A trio of sovereign wealth funds is in negotiations to take a stake in the UK-based private equity firm, in a move that could value the company at around £1.5bn.
1 min read · 04 January 2013
Trading of Peace Mark shares has been suspended following an indicative offer from CVC Asia Pacific, which has made four investments in Greater China in the last 12 months. Peace Mark has exclusive arrangements with brands including De Beers and Gucci-owned Boucheron and has a $241m market cap.
2 min read · 04 January 2013
CLSA Capital Partners has invested $30m to back the expansion of a fibreglass yarn-maker. Giving the firm an eventual 14 percent stake in Fulltech Fiber Glass, it is the seventh investment from the firm's pan-Asian growth fund.
2 min read · 04 January 2013
Shanghai will allow foreign investors to register as local firms, granting them a preferable tax and legal status.
2 min read · 04 January 2013
The private equity firms have agreed to sell Talecris Biotherapeutics, purchased for $590m in 2005, to Australian blood products company CSL.
2 min read · 04 January 2013
